
    
      This is a single-dose, open-label, single-center, randomized, four-way crossover study, ie,
      participants and investigator know the identity of the drug, which is assigned by chance,
      like flipping a coin, and participants may receive different interventions sequentially
      during the study. The study will consist of 4 treatment periods. A single dose of tapentadol
      (CG5503) will be administered orally with 240 mL of water under fasted conditions. All
      participants will receive 1 of the following 4 oral treatments in each period.

      Treatment A: One 25-mg tablet (25 mg) of tapentadol (CG5503) Treatment B: One 50-mg tablet
      (50 mg) of tapentadol (CG5503) Treatment C: One 100-mg tablet (100 mg) of tapentadol (CG5503)
      Treatment D: Two 100-mg tablets (200 mg) of tapentadol (CG5503) Each period will be separated
      by 7 - 14 days.
    
  